Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radiation zaps lingering brain tumors in lung cancer patients

NCT ID NCT06020066

Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether adding precise radiation (stereotactic radiosurgery) to standard drug therapy can better control brain metastases in people with non-small cell lung cancer. Participants have brain tumors that remain after 3-6 months of a targeted drug. The goal is to see if the combination delays cancer progression and improves survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
stereotactic radiotherapy (precise radiation beams)
What this could lead to
If successful, this approach could help control brain metastases in lung cancer patients, potentially delaying disease progression and improving survival without needing stronger drugs.
What could go wrong
This is a Phase 2 trial with 202 participants, so results are still preliminary. The added radiation may cause side effects like brain swelling or fatigue, and it may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

202 people

The number who actually took part.

Started

Aug 2023

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pathologically confirmed non-small cell lung cancer; * Clinical stage IV (AJCC, 8th edition, 2017); * EGFR mutations: EGFR L858R, EGFR exon 19 deletion; * Age ≥18 years; * KPS score ≥70; * Brain metastasis at the time of diagnosis; * Complete baseline imaging assessment of metastatic lesions, including enhanced MRI for brain; * Receiving first-line treatment with third-generation EGFR inhibitors; * After 3-6 months of third-generation EGFR inhibitor treatment, imaging review indicates no progression of extracranial lesions, and brain lesions are evaluated by thin-layer (1mm layer) enhanced MRI, meeting the following criteria: * No more than 10 remaining brain lesions; * The maximum diameter of the remaining brain lesions does not exceed 3cm; * At least one remaining brain lesion has a diameter greater than 5mm; * After evaluation by the researcher, all remaining brain lesions are suitable for stereotactic radiotherapy. * Patient informed consent. Exclusion Criteria: * Poor compliance with the study protocol in the investigator's opinion; * Patients withdrew their informed consent and requested to withdraw from the study; * Patients were unable to receive regular doses of third-generation EGFR inhibitors due to other underlying conditions, viral side effects, economic factors, etc. (e.g., continuous discontinuation for more than 1 week, cumulative discontinuation for more than 2 weeks). * Patients did not follow the protocol for follow-up visits as required by this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain metastases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer metastatic malignant neoplasm in the brain non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain metastases Non-small cell lung cancer

Contacts and locations

Locations

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, 200030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.